Literature DB >> 15950626

Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?

Bart C J M Fauser, Paul Devroey.   

Abstract

The use of GnRH antagonist rather than agonist cotreatment during ovarian hyperstimulation for IVF is not widely accepted. Possible benefits, current shortcomings, and avenues for future development are discussed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15950626     DOI： 10.1016/j.fertnstert.2005.02.011

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  15 in total

1.  GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.

Authors:  Yannis Prapas; Konstantinos Ravanos; Stamatios Petousis; Yannis Panagiotidis; Achilleas Papatheodorou; Chrysoula Margioula-Siarkou; Assunta Iuliano; Giuseppe Gullo; Nikos Prapas
Journal:  J Assist Reprod Genet       Date:  2017-08-03       Impact factor: 3.412

2.  The effects of GnRH antagonist on the endometrium of normally menstruating women.

Authors:  Porntip Sirayapiwat; Somchai Suwajanakorn; Surang Triratanachat; Somchai Niruthisard
Journal:  J Assist Reprod Genet       Date:  2007-11-30       Impact factor: 3.412

3.  Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study.

Authors:  Rafal Kurzawa; Przemyslaw Ciepiela; Tomasz Baczkowski; Krzysztof Safranow; Pawel Brelik
Journal:  J Assist Reprod Genet       Date:  2008-09-19       Impact factor: 3.412

4.  Precycle Estradiol in Synchronization and Scheduling of Antagonist Cycles.

Authors:  Shilpa Saple; Mukesh Agrawal; Simi Kawar
Journal:  J Obstet Gynaecol India       Date:  2016-04-29

5.  Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles.

Authors:  Qiaohong Lai; Hanwang Zhang; Guijing Zhu; Yufeng Li; Lei Jin; Long He; Zhijun Zhang; Ping Yang; Qilin Yu; Shu Zhang; Jun-Fa Xu; Cong-Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

6.  Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome.

Authors:  L Rinaldi; F Lisi; H Selman
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

7.  Early initiation of gonadotropin-releasing hormone antagonist in polycystic ovarian syndrome patients undergoing assisted reproduction: randomized controlled trial ISRCTN69937179.

Authors:  Mostafa I Abuzeid; Mohamed Mitwally; Yasmine M Abuzeid; Hammad A Bokhari; Mohammad Ashraf; Michael P Diamond
Journal:  J Assist Reprod Genet       Date:  2012-09-08       Impact factor: 3.412

8.  GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology.

Authors:  Ana Marcia M Cota; Joao Batista A Oliveira; Claudia G Petersen; Ana L Mauri; Fabiana C Massaro; Liliane F I Silva; Andreia Nicoletti; Mario Cavagna; Ricardo L R Baruffi; José G Franco
Journal:  Reprod Biol Endocrinol       Date:  2012-04-27       Impact factor: 5.211

9.  Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.

Authors:  Klaus F Bühler; Robert Fischer; Patrice Verpillat; Arthur Allignol; Sandra Guedes; Emmanuelle Boutmy; Wilma Bilger; Emilia Richter; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2021-06-16       Impact factor: 5.211

10.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.